A large proportion of patients with prostate cancer undergoing androgen deprivation therapy continue to die from non-cancer causes in the PSA era

British Journal of Medical and Surgical Urology

Volumn 2, Issue 5, 2009, Pages 191-196

  Wadhwa, Vivek K ^a   Weston, Robin ^a   Parr, Nigel J ^a  

^a WIRRAL UNIVERSITY TEACHING HOSPITAL   (United Kingdom)

Author keywords

Androgen antagonists; Cardiovascular; Cause of death; Prostate cancer

Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER MORTALITY; CANCER PATIENT; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER;

EID: 68349128503     PISSN: 18759742     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bjmsu.2009.06.004     Document Type: Article

References (12)

1. Cooperberg M.R., Grossfeld G.D., Lubeck D.P., and Carroll P.R. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95 (2003) 981-989
2. Byar D.P. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 32 (1973) 1126-1130
3. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the medical council trial. Br J Urol 79 (1997) 235-246
4. Brown B.W., Brauner C., and Minnotte M.C. Noncancer deaths in white adult cancer patients. J Natl Cancer Inst 85 (1993) 979-987
5. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
6. Huggins C., and Hodges C.V. Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
7. Kirk D. Timing and choice of androgen ablation. Prostate Cancer Prostatic Dis 7 (2004) 217-222
8. Studer U.E., Hauri D., Hanselmann S., Chollet D., Leisinger H.J., Gasser T., et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomised trial SAKK 08/88. J Clin Oncol 22 (2004) 4109-4118
9. Studer U.E., Whelan P., Albrecht W., Casselman J., de Reijke T., Hauri D., et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24 (2006) 1868-1876
10. Studer U.E., Collette L., Whelan P., Albrecht W., Casselman J., de Reijke T., et al. Using PSA to guide timing of androgen deprivation therapy in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 53 (2008) 941-949
11. Petersen R.O. What should you ask your pathologist when contemplating minimally invasive therapy. In: Dicker A.P., Merrick G.S., Waterman F.M., Valicenti R.K., and Gomella L.G. (Eds). Basic and advanced techniques in prostate brachytherapy. 1st ed. (2005), Taylor & Francis 17-26 [Chapter 3]
12. Fouad M.N., Mayo C.P., Funkhouser E.M., Hall H.I., Urban D.A., and Kiefe C.I. Comorbidity independently predicted death in older prostate cancer patients, more of whom died with than from their disease. J Clin Epidemiol 57 (2004) 721-729